Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset ECL

Coverage 92,266 Raw stories ingested 7,951 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,727 Assets with fetched stories

Cryptocurrencies BTC 4,245 ETH 3,075 SOL 1,750 XRP 1,686 USDC 965 HYPE 822

Stocks SPCX 879 MU 723 NVDA 684 MSFT 557 GOOGL 531 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,679 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 29s ago
FMP Forex News Fetch every 5 min 4m ago
CoinGecko News Fetch every 5 min 4m ago
FIO Stock News Fetch every 10 min 3m ago
Patria Stock News Fetch every 10 min 3m ago
Editorial rewrite Rewrite every minute 29s ago
Asset sync Assets every 1 hour 43m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-24 18:41 1d ago Published 2026-07-24 14:20 1d ago	Ecolab čeká růst tržeb i zisku ve 2. čtvrtletí Ecolab čeká za 2. čtvrtletí tržby 4,4 mld. USD, tedy růst o 9,3 %, a zisk 2,08 USD na akcii, což by znamenalo zlepšení o 10,1 %. Marže mohou tlačit nahoru vyšší náklady na komodity, logistiku a energie. ECL Ecolab	FMP Stock News	72
Original source text Key Takeaways ECL's Q2 revenues are estimated to rise 9.3%, while earnings are projected to improve 10.1%.High-Tech, Life Sciences, Digital and Pest Elimination are expected to remain key growth drivers.Higher commodity, logistics and energy costs may pressure margins before pricing fully catches up. Ecolab (ECL - Free Report) is scheduled to release second-quarter 2026 results on July 28, before the opening bell. In the last reported quarter, the company delivered earnings in line with the estimates. ECL’s earnings beat estimates in two of the trailing four quarters, missed once and met once, delivering an average surprise of 0.23%. Q2 Estimates Currently, the Zacks Consensus Estimate for revenues is pegged at $4.4 billion, indicating growth of 9.3% year over year. The consensus mark for earnings is pinned at $2.08 per share, indicating an improvement of 10.1%. Factors to Note Before ECL ReportsEcolab is expected to have delivered another quarter of organic growth, supported by continued value pricing, resilient demand across most end markets and sustained momentum in its higher-growth businesses. Global High-Tech, Digital, Life Sciences and Pest Elimination are likely to have remained the key growth drivers, benefiting from ongoing AI infrastructure investments, accelerating digital adoption, robust biopharmaceutical demand and continued customer adoption of connected pest management solutions. However, elevated commodity, logistics and energy costs, along with the temporary lag in pricing recovery, are expected to have pressured second-quarter margins and earnings growth. Within the Global Industrial segment, Global High-Tech is expected to have maintained strong double-digit growth, supported by continued investments in semiconductor fabrication facilities, AI-driven data center expansion and rising demand for advanced water management solutions. Life Sciences is also likely to have delivered another quarter of double-digit growth, aided by robust demand for bioprocessing solutions, expanding biologics production and favorable capacity utilization. Meanwhile, Food & Beverage is expected to have outperformed its underlying markets, supported by innovation and the company's One Ecolab strategy. Paper and Heavy Water businesses, however, likely remained relatively soft despite signs of stabilization and incremental gains from new business wins. The Global Institutional & Specialty segment is expected to have delivered steady growth, supported by continued value pricing, market share gains and demand from restaurant, lodging and quick-service restaurant customers. Specialty is likely to have remained a standout performer, benefiting from customer demand for productivity-enhancing and resource-efficient solutions that lower labor, water and energy costs. The company's One Ecolab initiative, including cross-selling efforts among its largest customers, is also expected to have supported revenue growth during the quarter. Per management, Ecolab expects second-quarter 2026 to serve as a transition period as elevated commodity, energy and logistics costs temporarily pressure earnings before pricing actions and energy surcharges are fully realized. While the company did not provide specific revenue or earnings per share (EPS) guidance for the quarter, it expects underlying performance to remain within its long-term adjusted EPS growth target of 12-15%, with higher commodity costs expected to reduce second-quarter EPS growth by a few percentage points. Pricing is anticipated to have accelerated through the quarter, allowing Ecolab to fully offset the dollar impact of higher input costs by the end of the second quarter. Meanwhile, favorable business mix, continued strength in higher-margin growth engines such as Global High-Tech and Life Sciences, SG&A productivity initiatives and digital efficiencies are expected to have partially cushioned inflationary pressures during the quarter. Investors will closely monitor management's commentary on pricing realization, margin recovery, demand trends across key end markets and the initial contribution and integration of the recently acquired CoolIT business, particularly as Ecolab enters the second half of 2026 with its full-year adjusted EPS growth outlook of 12-15% intact, excluding the temporary acquisition-related impact. Earnings Beat UnlikelyOur proven model does not predict an earnings beat for ECL this earnings season. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is not the case here. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.20%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #4 (Sell) at present. Stocks Worth a LookHere are some other medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS indicates an improvement of 10.9% from the year-ago reported figure. Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank of 3 at present. The company is set to release second-quarter 2026 results on Aug. 10. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.66%. The Zacks Consensus Estimate for ALC’s second-quarter EPS implies an improvement of 1.3% from the year-ago reported figure. Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Aug. 11. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates a gain of 16.4% from the year-ago reported figure.
	Saved 2026-07-03 16:22 22d ago Published 2026-07-03 11:10 22d ago	Ecolab kupuje CoolIT a posiluje chlazení pro AI Ecolab dokončil akvizici CoolIT za zhruba 4,75 miliardy USD a posiluje tím nabídku přímého kapalinového chlazení pro datová centra pro AI. Firma čeká, že její high-tech byznys dosáhne do roku 2030 tržeb 4 miliardy USD. ECL Ecolab	FMP Stock News	92
Original source text Key Takeaways Ecolab closed its $4.75B CoolIT deal, adding direct liquid cooling for AI data centers.CoolIT's technology complements Ecolab's water treatment and digital monitoring capabilities.Ecolab expects High-Tech annual sales to reach $4B by 2030, with about 25% margins. Ecolab (ECL - Free Report) completed its previously announced acquisition of direct liquid cooling specialist CoolIT Systems for approximately $4.75 billion, earlier than expected. The deal significantly strengthens Ecolab's presence in the rapidly expanding AI infrastructure market by adding advanced liquid cooling technologies for high-density data centers to its portfolio. From an investor's perspective, the acquisition marks another major step in Ecolab's strategy to transform its High-Tech business into a key long-term growth driver. By combining CoolIT's direct liquid cooling solutions with its existing water treatment and digital monitoring capabilities, Ecolab is positioning itself to capitalize on surging AI infrastructure investments while expanding its addressable market across semiconductor fabs, power generation and AI data centers. Management expects the High-Tech business to reach $4 billion in annual sales by 2030, supporting sustained organic revenue growth, margin expansion and double-digit earnings growth over the long term despite near-term acquisition-related costs. Likely Trend of ECL Stock Following the NewsShares of ECL have traded flat since the announcement yesterday. In the year-to-date period, shares of the company have gained 7.9% compared with the industry’s 16.1% growth. The S&P 500 increased 9.6% in the same time frame. The CoolIT acquisition is expected to significantly strengthen Ecolab's long-term growth prospects by establishing the company as a comprehensive solutions provider across the AI infrastructure value chain. The addition of direct liquid cooling technology complements Ecolab's existing expertise in ultra-pure water, power and digital optimization solutions, enabling it to offer integrated offerings for semiconductor manufacturing and AI data centers. As demand for high-density computing continues to rise, the acquisition should accelerate the expansion of Ecolab's High-Tech segment, deepen relationships with hyperscale customers and create cross-selling opportunities. Combined with the planned launch of its integrated 3D TRASAR cooling platform, the deal is expected to support faster revenue growth, higher operating margins and stronger recurring service revenues over the long term. ECL currently has a market capitalization of $78.34 billion. Image Source: Zacks Investment Research More on the NewsFollowing the acquisition, Ecolab plans to introduce an end-to-end 3D TRASAR cooling platform at the Supercomputing conference in November 2026. The platform will combine CoolIT's cooling distribution units and high-performance cold plates with Ecolab's digital 3D TRASAR optimization technology and advanced cooling fluids. Designed for next-generation AI systems, including NVIDIA's Vera Rubin and Grace Blackwell architectures, the solution will provide real-time monitoring of cooling system performance, helping customers reduce cooling power consumption, improve energy efficiency and move toward a near-zero water footprint through closed-loop cooling technologies. The integrated offering further expands Ecolab's capabilities across the AI infrastructure value chain, spanning ultra-pure water solutions for semiconductor manufacturing, water management for power generation and advanced liquid cooling for AI data centers. The acquisition also significantly scales Ecolab's Global High-Tech business. Annualized sales from the segment have increased from approximately $150 million in 2021 to nearly $1.5 billion in 2026 following the acquisitions of Ovivo and CoolIT. Management now expects the business to generate $4 billion in annual sales by 2030 while delivering operating margins of about 25%, making it the company's largest growth engine. Backed by annual growth exceeding 25%, the segment is projected to contribute more than two percentage points to Ecolab's annual sales growth. While the CoolIT acquisition is expected to create short-term earnings headwinds from non-cash amortization and financing costs, the company continues to project organic sales growth of 5-7%, annual operating margin expansion of 100-150 basis points and adjusted earnings per share (EPS) growth of 12-15% over the long term as acquisition synergies strengthen and the amortization impact from the Nalco acquisition begins to roll off after 2027. Favorable Industry Prospect for ECLPer a report by Grand View Research, the global data center liquid cooling market size was estimated at $6.65 billion in 2025 and is projected to reach $29.46 billion by 2033, expanding at a CAGR of 20.1% from 2026 to 2033. The rapid escalation of computing density, driven by AI, machine learning and high-performance computing workloads, is fueling the growth of the market. A Recent Development by ECLIn April, ECL introduced Ecolab Water Navigator IQ, an AI-enabled platform that provides businesses with a comprehensive, enterprise-wide view of water performance and converts insights into actionable outcomes. Water Navigator IQ unifies site-level data and predictive analytics in a single platform. It helps organizations track water usage, compare performance and align water strategies with business goals. ECL’s Zacks Rank & Key PicksCurrently, ECL carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) . Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%. West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
	Saved 2026-06-24 18:53 1mo ago Published 2026-06-24 13:16 1mo ago	Ecolab zvýšil organické tržby o 4 % v prvním čtvrtletí Ecolab v 1. čtvrtletí zvýšil organické tržby o 4 % díky cenám a objemu. Divize Global High-Tech rostla organicky o více než 20 % a Ecolab Digital překročil roční tempo tržeb 400 milionů USD. ECL Ecolab	FMP Stock News	78
Original source text Key Takeaways Ecolab posted 4% organic sales growth in Q1 2026, driven by pricing and volume gains.ECL's Global High-Tech business grew more than 20% organically on semiconductor demand.Ecolab Digital topped $400M in annualized revenue with AI and automation-driven solutions. Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a solid first-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist. This Zacks Rank #3 (Hold) stock has gained 2.3% in the year-to-date period compared with the industry’s 13% growth. The S&P 500 Composite has increased 8.9% during the same time frame. The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $75.8 billion. It projects 14.3% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met once, delivering an average surprise of 0.23%. Image Source: Zacks Investment Research Reasons Favoring Ecolab’s GrowthEcolab’s Global High-Tech Business & Digital Platform: Per management, Ecolab’s Global High-Tech business remains a key long-term growth driver, supported by rising semiconductor manufacturing and data-center infrastructure investments worldwide. In first-quarter 2026, the segment delivered more than 20% organic sales growth, driven by new business wins across microelectronics and data centers. Management also noted that the Ovivo Electronics acquisition strengthens Ecolab’s ultrapure water capabilities for semiconductor fabs and, together with the pending CoolIT Systems acquisition, is expected to create a roughly $1.5 billion Global High-Tech platform. Meanwhile, Ecolab Digital continues to scale as another important growth engine, with annualized revenues surpassing $400 million. Management highlighted that the platform leverages AI, predictive analytics, remote monitoring and automation to enhance customer productivity and sustainability outcomes, while addressing a $13 billion market opportunity, including nearly $3 billion within the existing customer base. Strong Product Portfolio With a Focus on R&D: In first-quarter 2026, Ecolab’s organic sales rose 4%, driven by 3% pricing and 1% volume growth, reflecting the strong value proposition of its portfolio. Per management, the company continues to benefit from a robust innovation pipeline, with increasing focus on digitally enabled solutions that enhance customer productivity and sustainability. Platforms like 3D TRASAR and other connected monitoring solutions are gaining traction by helping customers optimize water usage, energy consumption and operational efficiency. Management noted that these technology-driven offerings deliver measurable savings, strengthen long-term customer relationships and support premium pricing, reinforcing Ecolab’s competitive position across its end markets. Strong Q1 Results: ECL exited the first quarter of 2026 with in-line earnings and better-than-expected revenues. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of the adjusted operating margin bodes well for the stock. Per management, Ecolab’s performance in the first quarter was driven by strong value pricing, accelerated volume growth and improved productivity, demonstrating the strength of its technology- and service-led model. Its core businesses also delivered strong performance as Institutional and Specialty both improved, and Food & Beverage continued to significantly outperform market trends. These looked promising for the stock. A Factor That May Offset ECL’s GainsCost Fluctuations: Ecolab faces risks from raw material cost volatility, inflationary pressures and supply-chain disruptions, which could weigh on margins and profitability. Management expects commodity costs to rise at a high single-digit rate beginning in second-quarter 2026, primarily driven by energy-related expenses. The company remains exposed to fluctuations in raw material availability and pricing, as well as challenges in renewing supply agreements on favorable terms, which could adversely impact operating results, financial position and cash flows. Additionally, geopolitical tensions and broader economic slowdowns may disrupt global sourcing and supplier performance, limiting Ecolab’s ability to secure raw materials efficiently and at competitive prices. Estimate TrendEcolab is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $8.47 per share. The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $4.4 billion, indicating a 9.4% improvement from the year-ago quarter’s reported number. Key PicksSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) . Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%. West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.